N/A
N=6,623
Continuos Subcutaneous Insulin Infusion in Italy
Type 1 Diabetes
Bottom Line
View on ClinicalTrials.gov: NCT02620917 ↗Enrolled (actual)
6,623
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcome: Primary: Efficacy Assessed by Median of HbA1c, — 60 mmol/mol
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- University of Padova
- Primary completion
- Dec 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Efficacy Assessed by Median of HbA1c, |
60 | — |
| PRIMARY Patients With Severe Hypoglycemia |
331 | — |
| PRIMARY Number of Patients With Glycated Hemoglobin on Target |
1288; 445 | — |
| SECONDARY Number of Patients With HbA1c on Target Using Advanced Pump's Functions, CGM and CHO Counting |
1713; 515 | — |
Summary
This is an observational, multicenter, cross sectional study, collecting clinical and metabolic informations about patients treated with CSII in Italy.
Eligibility Criteria
Inclusion Criteria
- all patients treated with CSIIin Italy
Exclusion Criteria
- none
Data sourced from ClinicalTrials.gov (NCT02620917). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.